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Gang Li1, Fengjun Shi1*, Jingchen Liu2 and Ye Li2Abstract
Background: Recently, a number of studies have been performed to explore the association between CTLA-4 A49G
polymorphism and rheumatoid arthritis (RA). However, the results of previous works are still controversial and
ambiguous.
Methods: In this work, we attempted to perform an updated meta-analysis of available case–control study in order to
assess the association between CTLA-4 A49G polymorphism and RA risk. We searched the various citation databases
without limits on languages. Article searching was performed by screening the references of retrieved studies manually.
Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated to evaluate the strength of the association.
Results: We totally compiled 27 studies in 24 articles (9805 RA patients and 10691 control subjects) into our
meta-analysis work. We found significant association between CTL-A4 A49G polymorphism and RA risk (GG vs. AA:
OR = 1.13, 95% CI = 1.03–1.23; GA vs. AA: OR = 1.19, 95% CI = 1.07–1.33; GA + GG vs. AA: OR = 1.18, 95% CI = 1.07–1.29).
In the subgroup analysis by ethnicity, evidences of significantly increased risk was also found in both Asian (GG vs. AA:
OR = 1.34, 95% CI = 1.15–1.55; GA + GG vs. AA: OR = 1.24, 95% CI = 1.08–1.41) and Caucasian population (GA vs. AA:
OR = 1.19, 95% CI = 1.03–1.37; GA + GG vs. AA: OR = 1.14, 95% CI = 1.01–1.29). No evidence of publication bias was
found in this work.
Conclusions: Our meta-analysis suggests that CTLA-4 A49G polymorphism was associated with RA risk.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2014_157
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Rheumatoid arthritis (RA) is a common chronic inflam-
matory autoimmune disease characterized by significant
disability and early mortality. RA affects ~1% of the
adults worldwide [1]. Although its etiology has not been
determined, RA has been regarded as a complex auto-
immune disorder characterized by a chronic T-cell re-
sponse. So, genes involved in T-cell response regulation
might be important determinants of RA susceptibility.
The cytotoxic T-lymphocyte antigen 4 (CTLA-4) is
an inhibitory receptor predominantly expressed on the
activated and regulatory T lymphocytes [2]. It plays an
important role in regulating T-cell activation. Several* Correspondence: junfeng_shi001@163.com
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unless otherwise stated.studies have documented that polymorphism of CTLA-4
A49G have remarkable effects on the susceptibility to
autoimmunity [3]. A49G (rs231775) polymorphism, lo-
cated in the first exon region of CTLA-4 gene, was iden-
tified as a functional single nucleotide polymorphism with
a A to G change. This polymorphism has been shown to
be associated with the susceptibility of diverse diseases
[4-8], including RA. The results of previous reports on
the possible association of CTLA-4 A49G polymorphism
with RA risk remain controversial and ambiguous. To our
knowledge, the issue of whether CTLA-4 A49G poly-
morphism can increase RA risk remains largely uncertain.
A comprehensive meta-analysis can provide a reliable
estimate in genetic association studies. In this work, we
conducted a quantitative meta-analyses that increased
statistical power to derive a more precise estimation of
the relationship.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Study identification and selection
A systematic literature search was carried out in the
PubMed, IS Web and Chinese National Knowledge In-
frastructure (CNKI) database with the terms of “CTLA-4”,
“rheumatoid arthritis”, “polymorphism”, “variation”. Two
investigators independently screened the information in-
cluding the titles, abstracts and full texts to determine in-
clusion carefully. No language restrictions were used in our
literature search.
Data extraction
The following inclusion criteria were used to select re-
lated literatures for the meta-analysis: (1) studies about
the association between CTLA-4 A49G polymorphism
and RA risk; (2) a case-controlled RA study of CTLA-4
A49G polymorphism with complete genotype distribu-
tion data; (3) studies on sufficient data and the originalTable 1 Main characteristics of studies included in our work
First author Year Location Ethnicity
Seidl 1998 Germany Caucasian
Matsushita 1999 Japan Asian
Gonzalez-Escribano 1999 Spain Caucasian
Barton 2000 Spain Caucasian
Yanagawa 2000 Japan Asian
Hadj 2001 Tunisia African
Milicic 2001 UK Caucasian
Lee 2002 Korea Asian
Vaidya 2002 UK Caucasian
Lee 2003 China Asian
Liu 2004 Taiwan Asian
Barton 2004 UK Caucasian
Lei 2005 China Asian
Takeuchi 2006 Japan Asian
Suppiah 2006 UK Caucasian
Tsukahara 2008 Japan Asian
Walker 2009 Canada Caucasian
Munoz-Valle 2010 Mexico Mexican
Plant (F) 2010 France Caucasian
Plant (Ge) 2010 Germany Caucasian
Plant (Gr) 2010 Greece Caucasian
Plant (U) 2010 UK Caucasian
Benhatchi 2011 Slovakia Caucasian
Rocha 2011 Brail Caucasian
Tang 2013 China Asian
Alfadhli 2013 Kuwait Asian
Liu 2013 China Asiandata from case–control studies. The following information
were extracted from included studies: first author, year of
publication, original country, ethnicity of the sample and
genotype distributions.
Statistical analysis
The pooled odds ratios (ORs) with the corresponding
95% confidence intervals (95% CI) were used to evaluate
the strength of association between the polymorphism of
CTLA-4 A49G and RA risk. Four models were esti-
mated: the co-dominant model (GG vs. AA, GA vs. AA),
dominant model (GA +GG vs. AA) and recessive model
(GG vs. GA +AA), respectively. Subgroup analyses were
performed by ethnicity.
At first, we evaluated the HWE in the controls for
each study using chi-square and a P < 0.05 was consid-
ered as significant disequilibrium. Statistical heterogen-
eity among the studies was gauged by the Chi-squareCase/controls HWE
GG GA AA
37/68 138/210 83/179 0.88
200/56 199/72 62/22 0.98
10/30 63/103 65/172 0.06
14/12 57/70 65/62 0.44
29/78 50/88 6/34 0.56
23/68 27/62 10/20 0.33
63/73 223/213 135/166 0.94
41/49 35/29 10/8 0.49
20/45 65/158 38/146 0.97
103/85 67/100 16/18 0.32
14/21 42/50 9/10 0.07
34/29 55/68 43/59 0.49
148/86 138/125 40/39 0.84
49/44 39/49 12/11 0.88
40/92 144/241 92/142 0.85
636/181 668/194 186/73 0.23
177/179 554/576 409/493 0.87
42/34 102/82 55/83 0.22
96/15 315/75 273/72 0.77
37/94 111/83 72/83 0.44
26/33 133/107 113/147 0.15
146/410 451/1255 407/994 0.91
6/5 33/25 18/21 0.82
9/3 29/15 32/12 0.86
652/474 642/535 195/191 0.154
10/14 30/86 74/182 0.65
77/130 111/125 25/48 0.16
Table 2 Results of meta-analysis for CTLA-4 A49G polymorphism and RA risk
Groups GG vs AA GA vs AA GA + GG vs AA GG vs GA + AA
P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI)
Total 0.009 1.13 (1.03, 1.23) 0.001 1.19 (1.07, 1.33) 0.001 1.18 (1.07, 1.29) 0.66 1.03 (0.91, 1.17)
Asians 0.001 1.34 (1.15, 1.55) 0.083 1.16 (0.98, 1.37) 0.002 1.24 (1.08, 1.41) 0.099 1.14 (0.97, 1.35)
Caucasian 0.991 1.00 (0.89, 1.12) 0.015 1.19 (1.03, 1.37) 0.042 1.14 (1.01, 1.29) 0.51 0.93 (0.77, 1.14)
Figure 1 Forest plots for the overall association between CTLA-4 A49G polymorphism and RA risk A) GG vs. AA; B) GA vs. AA;
C) GA + GG vs. AA; D) GG vs. GA + GG.
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Table 3 Results of Egger’s test and Begg’s test
Comparison Egger’s test Begg’s test
t P 95% CI Z P
GG vs AA 0.31 0.76 (−0.92, 1.25) 0.67 0.51
GA vs AA 1.02 0.32 (−0.54, 1.61) 0.33 0.74
GA + GG vs AA 1.07 0.29 (−0.49, 1.55) 0.67 0.51
GG vs GA + AA −0.55 0.58 (−1.62, 0.94) 0.08 0.93
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indicates no significant heterogeneity existing among stud-
ies, and the pooled OR estimation was performed using
the fixed-effects model (the Mantel-Haenszel method).
Otherwise, the random-effects model (DerSimonian and
Laird method) was used. Potential publication bias of liter-
atures was analyzed through the Egger’s linear regression
test with a funnel plot. All statistical analyses were per-
formed with STATA version 11.0 (Stata Corporation,
College Station, TX). All the P values were calculated using
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in various databases. After literature selection, 43 studies
about the association of CTLA-4 A49G polymorphism


























Figure 2 Funnel plots for A49G polymorphism of CTLA-4 in RA disease Aretrieval. Among which, 16 studies were irrelevant. At
last, a total of 27 eligible independent case–control stud-
ies in 24 articles were included [9-33]. The characteristics
of selected studies are summarized in Table 1. All of the
studies indicated that the genotypic distribution of the con-
trols was consistent with Hardy-Weinberg equilibrium.
Quantitative synthesis
All of the main results of the meta-analysis were shown
in Table 2. Overall, significant associations between
CTLA-4 A49G polymorphism and RA risk was found
(GG vs. AA: OR = 1.13, 95% CI = 1.03–1.23; GA vs.
AA: OR = 1.19, 95% CI = 1.07–1.33; GA + GG vs. AA:
OR = 1.18, 95% CI = 1.07–1.29) (Figure 1). Next, we per-
formed a further analysis on data stratified by ethnicity
groups with the attempt to search for possible factors
that might impact the results. In the subgroup analysis
by ethnicity, evidences of significantly increased risk
was also found in both Asian (GG vs. AA: OR = 1.34,
95% CI = 1.15–1.55; GA + GG vs. AA: OR = 1.24, 95%
CI = 1.08–1.41) and Caucasian population (GA vs.
AA: OR = 1.19, 95% CI = 1.03–1.37; GA + GG vs. AA:
OR = 1.14, 95% CI = 1.01–1.29) in different genetic models.
Heterogeneity analysis
Significant heterogeneity existed in all four genetic
models (GG vs. AA: P = 0.016, I2 = 40.7%; GA vs. AA:
P = 0.01, I2 = 42.9%; GA + GG vs. AA: P = 0.027, I2 =























) GG vs. AA; B) GA vs. AA; C) GA+GG vs. AA; D) GG vs. GA+GG.
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all genetic models.
Sensitivity analyses and publication bias
Sensitivity analyses were performed to assess whether
each individual study can affect the final results by using
Begg’s test and Egger’s test. Neither the Begg’s test nor
the Egger’s test provided any obvious evidences of publi-
cation bias (Table 3). The shapes of the funnel plots
appeared to be symmetrical in all genetic models
(Figure 2). These results showed that no individual study
affected the final results in diverse genetic models using
the exclusion method step by step.
Discussion
Although many efforts have been devoted for decades,
the underlying molecular genetic basis of RA remains
largely unknown. Recently, researches in the genetic sus-
ceptibility to RA have led to growing attentions to the
study of association between gene polymorphisms and
RA [34]. Large and well-designed genotype-phenotype
investigations with robust statistical technical are re-
quired to detect these mild to moderate associations. Up
to date, the association studies have been performed for
CTLA-4 A49G polymorphism with respect to several
disease susceptibility, such as liver disease, pancreatic
cancer, primary biliary cirrhosis, etc. [5,35,36]. It has been
realized that CTLA-4 A49G polymorphism play important
role in disease disorders.
Several case–control studies have demonstrated incon-
sistent and even inverse relationship between CTLA-4
A49G polymorphism and RA risk. Until now, there are
still no consensus results on the association of CTLA-4
A49G polymorphism and susceptibility of RA. In this
work, we conducted a more comprehensive meta-
analysis on the CTLA-4 A49G polymorphism and RA.
For the overall data, it has been shown that CTLA-4
A49G polymorphism have an elevated association with
RA risk. In the subgroup analysis by ethnicity, results
suggested that strong evidences support the association
between RA risk and CTLA-4 A49G polymorphism in
both Asian and Caucasian populations. Previous meta-
analyses works have reported that the CTLA-4 A49G
polymorphism is associated with RA risk in Asians, but
not in Caucasians using limited data [37,38]. In our work,
we performed an up-dated meta-analyses, and found that
A49G polymorphism is associated with RA risk in both
Asians and Caucasians.
Many works have been devoted to examine the associ-
ation between polymorphisms and RA risk [39,40]. As
we know, genetic polymorphism of biomarkers is the
key factor leading to the susceptibility of diseases. Our
work suggests that CTLA-4 A49G polymorphism might
be a potential clinical marker for RA. Important clinicalinsights are emerging, and this polymorphism provides
new understanding of RA diagnostic advances. We pro-
vided useful reference for clinical medical treatment.
However, there are still some limitations in our meta-
analysis work. First, we were not able to take into ac-
count other factors because of lacking the original data,
such as alcohol addictive, inflammation and other dis-
ease that may influence the association estimates; Sec-
ond, although all eligible studies were summarized, the
total sample size might have not been enough to make a
convincing conclusion. So, when we performed stratified
analysis of ethnicity, the number of each subgroup was
relative smaller.
Conclusions
Our meta-analyses provided a more comprehensive evi-
dence of the association between CTLA-4 A49G poly-
morphism and RA risk. The result showed that CTLA-4
A49G polymorphism is associated with susceptibility
of RA.
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